Interaction with Strong CYP3A4/5 Inhibitors Strong CYP3A4/5 inhibitors can increase plasma concentrations of saxagliptin, potentially enhancing its pharmacological effects and adverse reactions
Metabolism 1978
[24] Finally, a 2020 Cochrane systematic review found insufficient evidence to suggest that metformin monotherapy reduced all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, or end-stage renal disease when compared to DPP-4 inhibitors for the treatment of type 2 diabetes
Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R
This doesnt mean you should avoid exercising on a GLP-1
This resource helps you avoid obvious risks before you look at individual sites